Fibroblast-derived CCL2 induces cancer stem cells--response.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

1. Crosstalk between Cancer Cells and Fibroblasts for the Production of Monocyte Chemoattractant Protein-1 in the Murine 4T1 Breast Cancer.Current issues in molecular biology · 2021
   Article
2. Identification of Four Genes as Prognosis Signatures in Lung Adenocarcinoma Microenvironment.Pharmacogenomics and personalized medicine · 2021
   Article
3. Targeting the CCL2-CCR2 signaling axis in cancer metastasis.Oncotarget · 2016
   Review
4. Cancer stem cell targeted therapy: progress amid controversies.Oncotarget · 2015
   Review
5. CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function.Cell reports · 2015
   Article

Corrections and comments

• Comment on
  CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells.2012
• Comment on
  Fibroblast-derived CCL2 induces cancer stem cells--letter.2013

Authors and funding

2 authors at 2 institutions in 2 countries.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as